KRAS and neoplasm: Collectively, these results indicate that deregulation of several key regulators systematically tunes the imbalance of unfavorable and favorable features, including tumor-suppressors TP53, ATM and SMAD4, oncogenes KRAS and E2F4, and genes with both potentials (MYCN and E2F4 [32, 33]).